Representative before the EPO

Company dna lds lazewski depo and partners
no operation time available
1 office
active in Legal Services

We have observed 4 EP applications Marek Lazewski has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13003327

Method for conducting a biomass torrefaction process, installation for conducting biomass process, torrified biomass and a method for puryfying flue gases from torrefaction process

IPC classification:
C10L 9/08
Agent:
Marek Lazewski, LDS Lazewski Depo & Partners
Status:
EXAMINATION IN PROGRESS
EP14001527

Animal model for Parkes-Weber syndrome

IPC classification:
A01K 67/027, A61K 36/77
Applicant:
Pharmaceutical Research Institute (Instytut Farmaceutyczny)
Applicant:
Warsaw Medical University (Warszawski Uniwersytet Medyczny)
Agent:
Marek Lazewski, LDS Lazewski Depo & Partners
Status:
PATENT GRANTED
EP14799527

7-AMINOCEPHALOSPORANIC ACID DERIVATIVE AS INHIBITOR OF IL-15 AND IL-2 ACTIVITY

IPC classification:
A61K 31/546, A61P 17/06, A61P 19/02, A61P 37/06
Applicant:
Warsaw Medical University (Warszawski Uniwersytet Medyczny)
Agent:
Marek Lazewski, LDS Lazewski Depo & Partners
Status:
EXAMINATION REQUESTED
EP15460037

ANTIPSORIATIC EMULSION COMPOSITION COMPRISING CEFAZOLIN

IPC classification:
A61K 9/107, A61K 9/113, A61K 31/546, A61K 47/02, A61K 47/06, A61K 47/08, A61K 47/10, A61K 47/18
Applicant:
Pharmaceutical Research Institute (Instytut Farmaceutyczny)
Applicant:
Warsaw Medical University (Warszawski Uniwersytet Medyczny)
Agent:
Marek Lazewski, LDS Lazewski Depo & Partners
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature